Spondyloarthritis & psoriatic arthritis
TNF-alpha inhibitors reduce the incidence of PsA in patients with psoriasis: a propensity score-matched cohort study
Authors' conclusion
This PS-matched study shows a clear benefit of TNFi vs nbUVB in PsA reduction in severe psoriasis patients over nearly a decade of therapy.
Study context
- Population
- Consecutive adults with severe psoriasis prescribed TNF inhibitors (TNFi) or narrow-band ultraviolet B (nbUVB) phototherapy between September 2005 and September 2010; rheumatologist assessment before therapymatched cohort
- Participants
- 946 adults
- Exposure
- TNFi vs nbUVB phototherapy
- TNFin = 497
- nbUVBn = 449reference
- Outcome
- PsA incidence
- Follow-up
- Over a decade
Methodological detailstime-dependent Cox model
- Time-dependent Cox model
Main finding
As reported in the abstract
PsA incidence rate per 100 patients
Incidence rate ratio (CI)P value
nbUVBvs TNFi
2.1(1.37–2.98)
P = 0.0002- TNFi vs nbUVB · time-dependent Cox model
- HR 0.32; P < 0.0001
Observational data: associations, not effects.
Further findings
Independent predictors of PsA
- Arthralgia, HR (P < 0.0001)
- 7.68
- Nail psoriasis, HR (P = 0.0004)
- 1.93
- Higher PASI score, HR per point (P = 0.0096)
- 1.03
Original publication
TNF-alpha inhibitors reduce the incidence of PsA in patients with psoriasis: a propensity score-matched cohort study. Rheumatology (Oxford). Published 3 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →